Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Purpurin 18** is a second-generation photosensitizer derived from chlorophyll, belonging to the chlorin class of compounds. It is utilized primarily in **photodynamic therapy (PDT)** for cancer treatment. Upon activation by light (wavelengths >650 nm), purpurin 18 produces reactive oxygen species, notably singlet oxygen, resulting in targeted oxidative damage to cancer cells while sparing normal tissue. Its mechanism of action centers on photodynamic generation of cytotoxic species and induction of apoptosis in tumor cells. Purpurin 18's advantages include a long absorption spectrum, high singlet oxygen quantum yield, and low dark toxicity. Major limitations are its hydrophobicity, poor water solubility, tendency to aggregate, and limited tumor selectivity—these are being addressed through formulations such as PEGylation and solid lipid nanoparticles to improve bioavailability and therapeutic effect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on purpurin 18.